ML213 50 mg | 99.74%
TargetMol
ML213 is a selective activator of Kv7.2 (KCNQ2) and Kv7.4 (KCNQ4) channels, enhances Kv7.2 and Kv7.4 channels with EC50s of 230 and 510 nM, respectively.
More Information Supplier PageML213
Search Results
Vardenafil hydrochloride trihydrate 100 mg | Purity Not Available
TargetMol
Vardenafil HCl Trihydrate is a new type PDE inhibitor with IC50 of 0.7 and 180 nM for PDE5 and PDE1, respectively.
More Information Supplier PageVardenafil hydrochloride trihydrate
FX1 5 mg | 99.68%
TargetMol
FX1
FX1 50 mg | 99.68%
TargetMol
FX1
FX1 25 mg | 99.68%
TargetMol
FX1
FX1 10 mg | 99.68%
TargetMol
FX1
FX1 100 mg | 99.68%
TargetMol
FX1
ML213 5 mg | 99.74%
TargetMol
ML213 is a selective activator of Kv7.2 (KCNQ2) and Kv7.4 (KCNQ4) channels, enhances Kv7.2 and Kv7.4 channels with EC50s of 230 and 510 nM, respectively.
More Information Supplier PageML213
Astragaloside II 5 mg | 99.70%
TargetMol
Astragaloside II is an effective MDR reversal agent and may be a potential adjunctive agent for hepatic cancer chemotherapy. Astragaloside II also induces osteogenic activities, differentiation, proliferation, and mineralization, through the bone morphogenetic protein-2/MAPK and Smad1/5/8 pathways.
More Information Supplier PageAstragaloside II
Astragaloside II 10 mg | 99.70%
TargetMol
Astragaloside II is an effective MDR reversal agent and may be a potential adjunctive agent for hepatic cancer chemotherapy. Astragaloside II also induces osteogenic activities, differentiation, proliferation, and mineralization, through the bone morphogenetic protein-2/MAPK and Smad1/5/8 pathways.
More Information Supplier PageAstragaloside II